10. Research and Development Contracts


NHLBI Total Research and Development Contract Obligations:*  Fiscal Years 2002–2012

NHLBI Total Research and Development Contract Obligations:* Fiscal Years 2002-2012

Text-only With Data Points

* For detailed data on contract-supported clinical trials, see Chapter 11.

NHLBI Total Research and Development Contract Obligations: Fiscal Years 2001–2011

Dollars (Thousands)

  FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012
Heart $214,971 $258,647 $245,881 $219,796 $213,320 $260,205 $296,445 $321,223 $303,251 $299,201 $269,968
Lung 16,578 11,745 14,131 20,946 25,902 15,191 20,249 17,710 47,777 25,338 22,646
Blood 26,751 20,082 25,460 27,831 23,629 20,446 22,093 22,164 28,864 43,752 39,789
Total $258,300A $290,474B $285,472C $268,573D $262,851E $295,842F $338,787G $361,097H $379,892I $368,291J $332,403K

A Includes Program Evaluation and IMPAC II Assessments of $35,827,000.
B Includes Program Evaluation and IMPAC II Assessments of $54,550,000.
C Includes Program Evaluation and IMPAC II Assessments of $57,545,722.
D Includes Program Evaluation and IMPAC II Assessments of $64,399,000.
E Includes Program Evaluation and IMPAC II Assessments of $67,795,000.
F Includes Program Evaluation and IMPAC II Assessments of $68,405,000.
G Includes Program Evaluation and IMPAC II Assessments of $77,487,000.
H Includes Program Evaluation and IMPAC II Assessments of $79,693,000.
I Includes Program Evaluation and IMPAC II Assessments of $83,834,100.
J Includes Program Evaluation and IMPAC II Assessments of $88,024,222.
K Includes Program Evaluation and IMPAC II Assessments of $86,618,720.
Note: From 2002 to 2006 the WHI was reported separately. In this table, it has been incorporated in the "Heart" line. 

Back to Top

Major NHLBI Research and Development Contracts by Program

Total Obligations Prior to FY 2012 Total FY 2012 Obligations Total Obligations to Date
Heart and Vascular Diseases

 

 

 

Action to Control Cardiovascular Risk in Diabetes Follow-On Study (ACCORDION) $13,250,149 $5,360,712 $18,610,861
Atherosclerosis Risk in Communities (ARIC) 172,181,383 16,608,970 188,790,353
Cardiovascular Health Study (CHS) 80,132,513 1,114,188 81,246,701
Coronary Artery Risk Development in Young Adults (CARDIA) 109,040,284 5,149,537 114,189,821
DNA Resequencing and Genotyping 38,483,962 6,465,315 44,949,277
Framingham Heart Study (FHS) 132,373,786 8,097,951 140,471,737
Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GenTAC):  National Registry 14,878,123 3,608,732 18,486,855
Global Health Centers of Excellence 17,007,036 2,664,485 19,671,521
Hispanic Community Health Study—Study of Latinos (HCHS-SOL) 56,644,388 318,346 56,962,734
Interagency Registry for Mechanical Circulatory Support (INTERMACS) 13,126,195 3,941,360 17,067,555
Jackson Heart Study (JHS) 43,376,798 5,185,422 48,562,220
Multi-Ethnic Study of Atherosclerosis (MESA) 108,794,927 11,969,995 120,764,922
NHLBI Gene Therapy Resource Program (GTRP) 29,188,977 9,823,650 39,012,627
Proteomics Initiative 191,642,369 17,263,177 208,905,546
Pumps for Kids, Infants, and Neonates (PumpKIN)* 18,551,904 6,643,880 25,195,784
Science Moving TowArds Research Translation and Therapy Program (SMARTT) 4,145,344 5,573,693 9,719,037
Lung Diseases      
Lung Tissue Research Consortium 37,852,716 3,905,131 41,757,847
Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) 32,697,717 2,235,206 34,932,923
Blood Diseases and Resources      
Maintenance of NHLBI Biological Specimen Repository 22,542,077 3,217,643 25,759,720
NHLBI–CDC Registry and Surveillance System in Hemoglobinopathies (RuSH) 10,628,679 631,637 11,260,316
Production Assistance for Cellular Therapies (PACT) 22,298,545 11,940,967 34,239,512
Recipient Epidemiology and Donor Study III (REDS-III)** 19,910,527 2,178,536 22,089,063

*    See Chapter 11 for PumpKIN clinical trial. 
**  Formerly known as Retrovirus Epidemiology Donor Study. 

Back to Top

Heart and Vascular Diseases

Action To Control Cardiovascular Risk in Diabetes Follow-On Study (ACCORDION), Initiated in Fiscal Year 2011

The purpose of the follow-up observational study (ACCORDION) is to obtain long-term (10 year average) data on the ACCORD* participants. Investigators are seeking to determine whether differences in mortality, CVD events, and microvascular diseases identified during the ACCORD trial persist or change over time and whether other differences will emerge. They will monitor long-term vascular outcomes from diabetes and the effects of glucose, blood pressure lowering, and lipid treatment on those outcomes. 

*  Total funding for ACCORD was $142,587,546 from 1999 to 2010. 

The ACCORD was a randomized clinical trial to evaluate the ability of three treatment strategies (intensive glycemic control, intensive blood pressure control, and fibrate treatment to raise HDL-cholesterol and lower triglycerides) to prevent major CVD events in patients with type 2 diabetes who were at high risk of CVD. 

After a mean 3.5 years of treatment, the intensive glycemic portion of the trial was stopped because patients in the intensive glycemic treatment group had an increased risk of all-cause mortality compared with patients in the standard treatment group even though they had a non-statistically significant 10 percent reduction in the composite primary outcome of nonfatal MI, nonfatal stroke, or CVD death. Participants in the intensive group were then transitioned to the standard treatment strategy. Initial follow-up found no overall benefit of intensive treatment (intensive blood pressure control or fibrate and statin) over standard treatment (normal blood pressure or statin). 

Obligations

Funding History:
Fiscal Year 2012—$5,360,712
Fiscal Year 2011—$13,250,149
Total Funding to Date—$18,610,861

Current Active Organization and Contract Number

  1. Wake Forest University
    Winston-Salem, North Carolina—26820110027C

Atherosclerosis Risk in Communities (ARIC), Initiated in Fiscal Year 1985

The ARIC is an epidemiology study comprising a prospective cohort component and a community surveillance component. The cohort component investigates the etiology of CHD and stroke in 15,792 participants, aged 46–64 years at baseline, by race and gender in four U.S. communities. The community surveillance component monitors trends in hospitalized myocardial infarction, fatal CHD, and heart failure (2005–2009) from the same communities. 

In 2011, the study began to reexamine the cohort participants with a focus on heart failure—a major epidemic in the rapidly aging U.S. population. Three of the cohort components represent the racial mix of their respective communities, and the fourth is exclusively black. 

Obligations

Funding History:
Fiscal Year 2012—$16,608,970
Fiscal Years 1985–2011—$172,181,383
Total Funding to Date—$188,790,353

Current Active Organizations and Contract Numbers

  1. University of North Carolina,
    Chapel Hill
    Chapel Hill, North Carolina     —268201100005C
  2. Baylor College of Medicine
    Houston, Texas—268201100006C
  3. University of North Carolina,
    Chapel Hill
    Chapel Hill, North Carolina     —268201100007C
  4. University of Minnesota, Twin Cities
    Minneapolis, Minnesota—268201100008C
  5. Johns Hopkins University
    Baltimore, Maryland—268201100009C
  6. Mississippi Medical Center
    Jackson, Mississippi  —268201100010C
  7. Brigham and Women's Hospital
    Boston, Massachusetts  —268201100011C
  8. University of North Carolina,
    Chapel Hill
    Chapel Hill, North Carolina     —268201100012C

Cardiovascular Health Study (CHS), Initiated in Fiscal Year 1988

The CHS is a population-based, longitudinal study of risk factors for development and progression of CHD and stroke in the elderly, 17 percent of whom are from minority populations. Extensive data and samples have been collected from nearly 6,000 participants since 1989–1990. The current CHS:  Core Support Phase provides partial support for an infrastructure to enable continued access to study resources and expertise, scientific collaborations, and mentorship of early-career investigators. 

Obligations

Funding History:
Fiscal Year 2012—$1,114,188
Fiscal Years 1988–2011—$80,132,513
Total Funding to Date—$81,246,701

Current Active Organization and Contract Number

  1. University of Washington
    Seattle, Washington  —268200800007C

Coronary Artery Risk Development in Young Adults (CARDIA), Initiated in Fiscal Year 1984

The CARDIA is a long-term study that examines the evolution of CVD risk factors, subclinical atherosclerosis, and early clinical events in persons aged 18–30 years in 1985–1986. The study collects information on body mass index, diet, physical activity, genetics, cognitive functioning, serologic and metabolic components, inflammatory markers, and other subclinical measures of heart disease, pulmonary function, and behavioral and environmental factors. Fifty percent of the participants are black. 

Obligations

Funding History:
Fiscal Year 2012—$5,149,537
Fiscal Years 1984–2011—$109,040,284
Total Funding to Date—$114,189,821

Current Active Organizations and Contract Numbers

  1. Johns Hopkins University
    Baltimore, Maryland—268200900041C
  2. University of Alabama at Birmingham
    Birmingham, Alabama  —HC-48047
  3. University of Minnesota, Twin Cities
    Minneapolis, Minnesota      —HC-48048
  4. Northwestern University
    Chicago, Illinois —HC-48049
  5. Kaiser Permanente Division of Research
    Oakland, California —HC-48050
  6. University of Alabama at Birmingham
    Birmingham, Alabama  —HC-95095

DNA Resequencing and Genotyping Program, Initiated in Fiscal Year 2004

The purpose of this program is to provide high-quality, high-volume resequencing and genotyping of candidate genomic regions potentially important in the disease pathways of heart, lung, and blood diseases and sleep disorders. The information obtained will enable ongoing investigations to elucidate the specific genetic components involved in the causes for, variable outcomes of, and progression of the diseases and disorders. 

Obligations

Funding History:
Fiscal Year 2012—$6,465,315
Fiscal Years 2004–2011—$38,483,962
Total Funding to Date—$44,949,277

Current Active Organization and Contract Number

  1. University of Washington
    Seattle, Washington  —268201100037C

Framingham Heart Study (FHS), Initiated in Fiscal Year 1948

The original Framingham Heart Study was designed as a longitudinal investigation of constitutional and environmental factors influencing the development of CVD in individuals free of CVD symptoms at the outset. Of the original 5,209 participants, about 104 are still alive. In 1971, the Framingham Offspring Study was initiated to assess familial and genetic factors associated with CHD. More than 5,000 offspring (and their spouses) were included. In 2002, a third-generation cohort consisting of approximately 4,000 grandchildren was added to permit examination of numerous hypotheses about the genetic contribution to CVD and CVD risk factors. Additional goals include identifying new risk factors for cardiovascular, lung, and blood diseases and developing new imaging tests that can detect very early stages of coronary atherosclerosis in otherwise healthy adults. 

In 2009, the Omni Group 1 and Omni Group 2 cohorts were integrated into the NHLBI contract for the FHS. The Omni cohorts consist of minority residents of Framingham, Massachusetts (about 500 and 400 participants in Omni Group 1 and Omni Group 2, respectively), and were previously identified, recruited, and examined through NHLBI investigator-initiated grants. They were added to the FHS to reflect the growing diversity of the community. 

Obligations

Funding History:
Fiscal Year 2012—$8,097,951
Fiscal Years 1983–2011—$132,373,786
Total Funding to Date—$140,471,737

Current Active Organization and Contract Number

  1. Boston University Medical Center
    Boston, Massachusetts  —HC-25195

Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GenTAC):  National Registry, Initiated in Fiscal Year 2006

The purpose of this program is to establish a registry of patients with genetic conditions that may be related to thoracic aortic aneurysms and to collect medical data and biologic specimens. The specimens and database are available to qualified investigators for research to advance the clinical management of genetically induced thoracic aortic aneurysms and other cardiovascular complications. Individuals with 1 of 12 conditions—including connective tissue diseases, such as Marfan, Loeys-Dietz, and Ehlers Danlos (vascular type) Syndromes, Turner Syndrome, and bicuspid aortic valve—are eligible to enroll in GenTAC. To date, 3,100 individuals are enrolled in the registry. 

Obligations

Funding History:
Fiscal Year 2012—$3,608,732
Fiscal Years 2006–2011—$14,878,123
Total Funding to Date—$18,486,855

Current Active Organization and Contract Number

  1. RTI International
    Research Triangle Park,
    North Carolina  —268201000048C

Global Health Centers of Excellence, Initiated in Fiscal Year 2009

The purpose of this program is to support a worldwide network of research and training centers to prevent and control chronic cardiovascular and pulmonary diseases in developing countries. The NHLBI joined with Minneapolis-based UnitedHealth Group's Chronic Disease Initiative in establishing the UnitedHealth and NHLBI Collaborating Centers of Excellence network. Each center is led by a research institution in a developing country that is paired with at least one partner academic institution in a developed country to enhance research and training opportunities. 

Obligations

Funding History
Fiscal Year 2012—$2,664,485
Fiscal Years 2009–2011—$17,007,036
Total Funding to Date—$19,671,521

Current Active Organizations and Contract Numbers

  1. Public Health Foundation of India
    New Delhi, India —268200900026C
  2. The George Institute for
    International Health
    Beijing, China   —268200900027C
  3. Instituto de Nutrición de Centro
    América y Panamá
    Guatemala City, Guatemala   —268200900028C
  4. Institute for Clinical Effectiveness
    and Health Policy
    Buenos Aires, Argentina —268200900029C
  5. University of Cape Town
    Cape Town, South Africa —268200900030C
  6. Moi University School of Medicine
    Eldoret, Kenya  —268200900031C
  7. International Centre for Diarrhoeal
    Disease Research, Bangladesh
    Dhaka, Bangladesh  —268200900032C
  8. Universidad Peruana Cayetano
    Heredia
    Lima, Peru    —268200900033C
  9. Westat
    Rockville, Maryland —268200900034C

Hispanic Community Health Study—Study of Latinos (HCHS-SOL), Initiated in Fiscal Year 2006

The purpose of this program is to determine the prevalence of and risk factors for cardiovascular and lung diseases in Hispanic populations and the role of cultural adaptation and disparities in development of these and other chronic diseases. The multicenter, 6.5-year epidemiology study comprises more than 16,400 Hispanics, aged 18–74 years, who self-identify as being of Mexican, Puerto Rican, Cuban, Dominican, or Central or South American heritage. 

Obligations

Funding History:
Fiscal Year 2012—$318,346
Fiscal Years 2006–2011—$56,644,388
Total Funding to Date—$56,962,734

Current Active Organizations and Contract Numbers

  1. University of Miami
    Miami, Florida —HC-65234
  2. Northwestern University
    Chicago, Illinois —HC-65236
  3. San Diego State University
    San Diego, California   —HC-65237

Interagency Registry for Mechanical Circulatory Support (INTERMACS), Initiated in Fiscal Year 2005

The INTERMACS is a national registry for patients who are receiving mechanical circulatory support device (MCSD) therapy to treat advanced heart failure. The registry collects and analyzes clinical and laboratory data and tissue samples from patients who receive MCSDs as destination therapy for end-stage heart failure at 119 participating sites. 

Obligations

Funding History:
Fiscal Year 2012—$3,941,360
Fiscal Years 2005–2011—$13,126,195
Total Funding to Date—$17,067,555

Current Active Organization and Contract Number

  1. University of Alabama
    Birmingham, Alabama—268201100025C

Jackson Heart Study (JHS), Initiated in Fiscal Year 1998

The JHS is an epidemiologic study of CVD in blacks in Jackson, Mississippi, similar to established studies in Framingham, Massachusetts, and Honolulu, Hawaii. The goal of the study is to identify factors related to the development and progression of CVD in blacks. The JHS conducts a variety of community education and outreach activities to promote healthy lifestyles to reduce disease burden. In addition, the JHS seeks to build research capabilities in minority institutions, address the critical shortage of minority investigators in epidemiology and prevention, and reduce barriers to dissemination and use of health information in a minority population. 

Obligations

Funding History:
Fiscal Year 2012—$5,185,422
Fiscal Years 1998–2011—$43,376,798
Total Funding to Date—$48,562,220

Current Active Organizations and Contract Numbers

  1. Jackson State University
    Jackson, Mississippi      —HC-95170
  2. Mississippi Medical Center
    Jackson, Mississippi      —HC-95171
  3. Tougaloo College
    Tougaloo, Mississippi   —HC-95172

Multi-Ethnic Study of Atherosclerosis (MESA), Initiated in Fiscal Year 1999

The purpose of this study is to investigate the prevalence, correlates, and progression of subclinical CVD (i.e. , disease detected noninvasively before it has produced clinical signs and symptoms). The cohort of 6,814 participants is 38 percent white, 28 percent black, 22 percent Hispanic, and 12 percent Asian. A fifth examination, completed in February 2012, included a repeat measurement of cardiac function with MRI to assess changes over time. Periodic monitoring of participants to identify recent hospitalizations and other clinical events will continue. 

Obligations

Funding History:
Fiscal Year 2012—$11,969,995
Fiscal Years 1999–2011—$108,794,927
Total Funding to Date—$120,764,922

Current Active Organizations and Contract Numbers

  1. University of Washington
    Seattle, Washington —HC-95159
  2. University of California, Los Angeles
    Los Angeles, California  —HC-95160
  3. Columbia University
    New York, New York    —HC-95161
  4. Johns Hopkins University
    Baltimore, Maryland    —HC-95162
  5. University of Minnesota, Twin Cities
    Minneapolis, Minnesota       —HC-95163
  6. Northwestern University
    Chicago, Illinois —HC-95164
  7. Wake Forest University School of Medicine
    Winston-Salem, North Carolina —HC-95165
  8. University of Vermont
    Colchester, Vermont     —HC-95166
  9. Johns Hopkins University
    Baltimore, Maryland    —HC-95168

NHLBI Gene Therapy Resource Program (GTRP), Initiated in Fiscal Year 2007

The purpose of this program is to promote the translation of basic gene therapy research into clinical intervention for heart, lung, and blood diseases. The program provides resources in the form of preclinical- and clinical-grade vector production; pharmacology and toxicology testing on animals; immunology testing; clinical trials funding assistance; and regulatory support for gene therapy research primarily in heart, lung, and blood diseases. 

Obligations

Funding History:
Fiscal Year 2012—$9,823,650
Fiscal Years 2007–2011—$29,188,977
Total Funding to Date—$39,012,627

Current Active Organizations and Contract Numbers

  1. Social and Scientific Systems, Inc. 
    Silver Spring, Maryland   —268201200002I
  2. Lovelace Biomedical Research and
    Education Institute
    Albuquerque, New Mexico—268201200003I
  3. University of Pennsylvania
    Philadelphia, Pennsylvania   —2682012000041C
  4. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania—268201200004I
  5. Indiana University
    Indianapolis, Indiana—268201200005I

Proteomics Initiative, Initiated in Fiscal Year 2002

The purpose of this program is to establish highly interactive, multidisciplinary centers to enhance and develop innovative proteomic technologies directed to relevant biologic questions associated with heart, lung, blood, and sleep health and disease. 

Obligations

Funding History:
Fiscal Year 2012—$17,263,177
Fiscal Years 2002–2011—$191,642,369
Total Funding to Date—$208,905,546

Current Active Organizations and Contract Numbers

  1. Boston University
    Boston, Massachusetts—268201000031C
  2. Johns Hopkins University
    Baltimore, Maryland—268201000032C
  3. Massachusetts General Hospital
    Boston, Massachusetts—268201000033C
  4. Stanford University
    Stanford, California—268201000034C
  5. University of California, Los Angeles
    Los Angeles, California  —268201000035C
  6. University of Texas
    San Antonio, Texas—268201000036C
  7. University of Texas
    Galveston, Texas—268201000037C

Pumps for Kids, Infants, and Neonates (PumpKIN), Initiated in Fiscal Year 2010

The purpose of this program is to support technologies that will expand life-saving options for infants and children who are born with congenital heart defects or those who develop heart failure. Investigators are seeking to complete animal studies and other preclinical tests for the most promising devices in order to gain approval from the FDA to begin clinical testing. 

Obligations

Funding History:
Fiscal Year 2012—$6,643,880
Fiscal Years 2010–2011—$18,551,904
Total Funding to Date—$25,195,784

Current Active Organizations and Contract Numbers

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania—268201000012C
  2. Jarvik Heart, Inc. 
    New York, New York—268201000013C
  3. University of Maryland
    Baltimore, Maryland—268201000014C
  4. Ension, Inc. 
    Pittsburgh, Pennsylvania—268201000015C

Science Moving TowArds Research Translation and Therapy Program (SMARTT), Initiated in Fiscal Year 2011

The purpose of this program is to support the transition of potential new therapies for heart, lung, and blood diseases from discovery in the lab to the testing needed to establish their safety and effectiveness in people. The SMARTT program provides tailored pharmacology and toxicology testing, manufacturing services, and regulatory support to investigators to expedite the transition of their discoveries to the clinic. 

Obligations

Funding History:
Fiscal Year 2012—$5,573,693
Fiscal Year 2011—$4,145,344
Total Funding to Date—$9,719,037

Current Active Organizations and Contract Numbers

  1. Advanced BioScience
    Laboratories, Inc. 
    Rockville, Maryland —268201100014C
  2. SRI International
    Menlo Park, California   —268201100015C
  3. RTI International
    Research Triangle Park,
    North Carolina  —268201100016C
  4. SRI International
    Menlo Park, California  —268201000017C

Lung Diseases

Lung Tissue Research Consortium, Initiated in Fiscal Year 2004

The purpose of this program is to establish a consortium for collecting lung tissues and preparing and distributing them for research. Scientists are seeking to improve management of lung diseases by increasing understanding of the pathogenetic mechanisms of lung diseases through molecular histopathological studies of tissues with and without disease. Primary emphases are on COPD and idiopathic pulmonary fibrosis. 

Obligations

Funding History:
Fiscal Year 2012—$3,905,131
Fiscal Years 2004–2011—$37,852,716
Total Funding to Date—$41,757,847

Current Active Organizations and Contract Numbers

  1. University of Michigan
    Ann Arbor, Michigan—268201100018C
  2. University of Pittsburgh
    Pittsburgh, Pennsylvania—268201100019C
  3. Mayo Clinic College of Medicine
    Rochester, New York—268201100020C
  4. Temple University
    Philadelphia, Pennsylvania     —268201100021C
  5. National Jewish Health
    Denver, Colorado      —268201100023C

Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), Initiated in Fiscal Year 2009

The objectives of this study are to define pathogenetically homogeneous subgroups of COPD subjects on the basis of biomarkers, genotypes, and computed tomography images and to identify immediate outcome measures for use in future clinical studies. Secondary aims are to clarify the natural history of COPD; develop bioinformatic resources that will enable the use and sharing of data in studies of COPD and related diseases; and create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD. 

Obligations

Funding History:
Fiscal Year 2012—$2,235,206
Fiscal Years 2009–2011—$32,697,717
Total Funding to Date—$34,932,923

Current Active Organizations and Contract Numbers

  1. University of California, Los Angeles
    Los Angeles, California—268200900015C
  2. University of Michigan
    Ann Arbor, Michigan—268200900016C
  3. Columbia University
    New York, New York—268200900017C
  4. University of Utah
    Salt Lake City, Utah—268200900018C
  5. Wake Forest University
    Winston-Salem, North Carolina—268200900019C
  6. University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina—268200900020C

Blood Diseases and Resources

Maintenance of NHLBI Biological Specimen Repository, Initiated in Fiscal Year 1998

The purpose of this project is to establish an NHLBI Biological Specimen Repository for blood specimens from Institute-supported research. The Repository monitors storage, labeling, and testing of the specimens, and administers safe shipment of precise sample aliquots to approved investigators for future studies. 

Obligations

Funding History:
Fiscal Year 2012—$3,217,643
Fiscal Years 1998–2011—$22,542,077
Total Funding to Date—$25,759,720

Current Active Organization and Contract Number

  1. SeraCare Life Sciences, Inc. 
    Rockville, Maryland —268201100031C

NHLBI–CDC Registry and Surveillance System in Hemoglobinopathies (RuSH), Initiated in Fiscal Year 2009

The purpose of this pilot program is to test the feasibility of developing a national data system that will enable investigators to estimate the number of people who have SCD, thalassemias, and hemoglobinopathies and to describe their sociodemographic characteristics. The Institute, along with the CDC, has created newborn screening programs with State health departments in California, Florida, Georgia, Michigan, New York, North Carolina, and Pennsylvania. 

Obligations

Funding History:
Fiscal Year 2012—$631,637
Fiscal Years 2009–2011—$10,628,679
Total Funding to Date—$11,260,316

Current Active Organization and Contract Number

  1. Centers for Disease Control and Prevention
    Atlanta, Georgia —HR-9045

Production Assistance for Cellular Therapies (PACT), Initiated in Fiscal Year 2010

The purpose of this program is to facilitate the transfer of innovative cellular therapies from the bench to the bedside. The PACT offers assistance to investigators in areas ranging from translational development to production of a product for use in human clinical trials. 

Obligations

Funding History:
Fiscal Year 2012—$11,940,967
Fiscal Years 2010–2011—$22,298,545
Total Funding to Date—$34,239,512

Current Active Organizations and Contract Numbers

  1. EMMES Corporation
    Rockville, Maryland —268201000006C
  2. Baylor College of Medicine
    Houston, Texas—268201000007C
  3. University of Minnesota
    Minneapolis, Minnesota—268201000008C
  4. Immune Disease Institutes
    Boston, Massachusetts  —268201000009C
  5. University of Wisconsin
    Madison, Wisconsin  —268201000010C
  6. Beckman Research Institutes
    Duarte, California     —268201000011C

Recipient Epidemiology and Donor Study-III (REDS-III),* Initiated in Fiscal Year 2011

The purpose of this program is to conduct research to improve transfusion practices and the safety and adequacy of the blood supply in the United States and in countries affected by the AIDS epidemic. The domestic component consists of four research hubs, and the international component consists of collaborators from blood centers in Brazil, China, and South Africa. 

Building on the findings of previous REDS and REDS II programs, the REDS-III international program focuses on identifying ways to reduce and prevent the transmission of HIV/AIDS and other known and emerging infectious agents through transmission. 

Obligations

Funding History:
Fiscal Year 2012—$2,178,536
Fiscal Year 2011—$19,910,527
Total Funding to Date—$22,089,063

Current Active Organizations and Contract Numbers

    1. Blood System Research, Inc. 
      San Francisco, California—268201100001
    2. RTI International
      Research Triangle Park,
      North Carolina—268201100002
    3. Blood Center of Southeastern
      Wisconsin
      Milwaukee, Wisconsin—268201100003
    4. Institute for Transfusion Medicine
      Pittsburgh, Pennsylvania   —268201100004
    5. University of California,
      San Francisco
      San Francisco, California—268201100005
    6. Yale University
      New Haven, Connecticut—268201100006
    7. Blood System Research, Inc. (Brazil)
      San Francisco, California—268201100007
    8. Johns Hopkins University (China)
      Baltimore, Maryland—268201100008
    9. University of California,
      San Francisco (South Africa)
      San Francisco, California—268201100009

    *  Formerly known as Retrovirus Epidemiology Donor Study. REDS: Total funding for FY 1989–2004, $73,774,125. REDS II: Total funding for FY 2005–2010, $53,016,894. 

    Back to Top

    « Fact Book Table of Contents

Skip footer links and go to content
Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon